Plasma levels of IL-6 in patients with untreated major depressive disorder: comparison with catecholamine metabolites
Reiji Yoshimura,1,* Taro Kishi,2,* Nakao Iwata2 1Department of Psychiatry, University of Occupational and Environmental Health, Kitakyushu, Fukuoka 8078555, Japan; 2Department of Psychiatry, Fujita Medical University, Toyoake Aichi 4701192, Japan*These authors contributed equally to this workCorresp...
Guardado en:
Autores principales: | Yoshimura R, Kishi T, Iwata N |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2019
|
Materias: | |
Acceso en línea: | https://doaj.org/article/18f4f185196d4ecbbb069589b685b569 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Escitalopram versus paroxetine controlled release in major depressive disorder: a randomized trial
por: Kishi T, et al.
Publicado: (2017) -
Factors Affecting Post-Stroke Depression in Acute Ischemic Stroke Patients after 3 Months
por: Chan-Hyuk Lee, et al.
Publicado: (2021) -
Factors impacting the efficacy of venlafaxine extended release 75–225 mg/day in patients with major depressive disorder: exploratory post hoc subgroup analyses of a randomized, double-blind, placebo-controlled study in Japan
por: Watanabe Y, et al.
Publicado: (2018) -
Hashimoto encephalopathy with high plasma monoamine metabolite levels: a case report
por: Horikoshi S, et al.
Publicado: (2017) -
Influence of fluvoxamine on plasma interleukin-6 or clinical improvement in patients with major depressive disorder
por: Yoshimura R, et al.
Publicado: (2017)